Elsevier

Regulatory Peptides

Volume 74, Issues 2–3, 30 June 1998, Pages 185-192
Regulatory Peptides

Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow

https://doi.org/10.1016/S0167-0115(98)00039-1Get rights and content

Abstract

The present study investigated the effects of three newly synthesized AngIV analogs (Lysine1-AngIV, Norleucine1-AngIV, and Norleucinal) on cerebral blood flow (CBF) in anesthetized Sprague–Dawley rats utilizing laser-Doppler flowmetry. The results indicate that internal carotid infusions of AngIV, Norleucine1-AngIV, Norleucinal, and Lysine1-AngIV increased CBF above baseline by 25, 32, 33 and 44%, respectively, without changing systemic arterial blood pressure. In a second experiment separate groups of rats were pretreated with nitric oxide (NO) synthase inhibitor, Nw-nitro-l-arginine methyl ester (l-NAME) or saline, followed by AngIV or Norleucinal for the purpose of evaluating the hypothesis that the mechanism of action of these compounds is linked to the release of NO. Pretreatment with saline followed by AngIV and Norleucinal increased CBF by 29 and 39%, respectively, while pretreatment with l-NAME blocked the vasodilatory effects of AngIV and Norleucinal, suggesting that the increment in blood flow induced by these compounds is dependent upon the synthesis and release of NO from vascular endothelial cells.

Introduction

An ischemic insult to the brain can lead to significant cell losses especially in the CA1 field of the hippocampus 1, 2, 3, 4. Within this field pyramidal neurons are lost in proportion to the severity of the ischemia, thus compromising this structure's ability to mediate learning acquisition and memory processing 5, 6, 7, 8, 9, 10. The CA1 field is also targeted during the progression of Alzheimer's disease (AD) with concomitant cognitive impairment 11, 12. These AD-associated cell losses have been attributed to insufficient microcirculation [13]. Thus, an understanding of the mechanisms regulating cerebral blood flow (CBF) may be relevant to these cognitive dysfunctions [3].

Earlier reports have suggested that the octapeptide, angiotensin II (AngII), may play a role in CBF regulation 14, 15, 16. Recent evidence supports the notion that an AngII degradative product, the hexapeptide angiotensin IV (AngIV), may also serve a critical function in the control of CBF 17, 18. Along these lines Näveri et al. [19]reported that intravenous infusions of AngIV in rats reversed the reduction in CBF resulting from experimentally-induced subarachnoid hemorrhage (SAH) by increasing CBF 45–80% above baseline over a 60-min period. Pretreatment with a non-selective AT1 and AT2 receptor antagonist, Sar1, Ile8 AngII (Sarile), failed to block this AngIV-induced vasodilation response, suggesting that AngIV-induced elevations in blood flow are mediated by a receptor subtype other than AT1 and AT2.

Our laboratory has discovered what may be a novel angiotensin receptor subtype, classified AT4 [20], that displays high affinity for AngIV 21, 22, however, the molecular structure of this receptor has not been determined. The initial discovery was made in bovine adrenal tissue but has since been extended to include other tissues such as cultured endothelial and smooth muscle cells 22, 23, 24. Therefore, it is possible that this receptor subtype is responsible for mediating the AngIV-induced increases in CBF reported by Näveri et al. [19]. The development and availability of Losartan (Dup 753), a specific AT1 receptor subtype antagonist [25], and a newly synthesized specific AT4 receptor subtype antagonist, Divalinal-AngIV [26], now makes it possible to differentiate the roles of AngII and AngIV. We have utilized laser-Doppler flowmetry to demonstrate that intra-arterial infusions of AngII reduced CBF by 23%, whereas, infusions of AngIV increased CBF in a dose-dependent fashion [27]. Further, these AngII-induced reductions in CBF could be inhibited by pre-treatment with Losartan, while pre-treatment with Divalinal-AngIV completely abolished the AngIV-induced vasodilation response. There were no receptor antagonist cross-over effects suggesting that AngII acts at the AT1 receptor to reduce CBF, while AngIV binds at the AT4 subtype to increase CBF.

As mentioned above, vascular endothelial cells possess AT4 receptors [24]. It has also been shown that a vascular endothelial cell nitric oxide (NO)-mediated mechanism decreased infarction volume after middle cerebral artery occlusion by increasing regional CBF in rats [30]. Taken together, we speculated that AngIV-induced vasodilation may be caused by AngIV directly (or indirectly) activating the synthesis and release of NO in vascular endothelial cells. Results from a recent study by Patel and Block [31]support this notion in that AngIV enhanced the catalytic activity of endothelial cell NO synthase (ecNOS) and the production of cGMP in porcine pulmonary artery endothelial cells (PAEC). These investigators predicted that Divalinal-AngIV would block ecNOS activation, and consequently NO production in PAEC (J.M. Patel, personal communication).

Given the recent findings on the effects of AngIV on cerebral circulation 19, 22it appears that AngIV participates in the regulation of CBF in the microvasculature. However, native AngIV possesses a short metabolic half-life (Harding, personal communication; [28]), consequently, there is a need to develop AngIV analogs that are resistant to systemic metabolic breakdown and display high-affinity binding at the AT4 receptor. Our laboratory has investigated the structure-binding characteristics of AngIV with the AT4 receptor [29], and we have recently synthesized several AngIV analogs. Thus, the purpose of the present study was to investigate the effects of AngIV and three AngIV analogs, Lysine1-AngIV (Lys1-AngIV), Norleucine1-AngIV (Nle1-AngIV) and Norleucinal on CBF regulation, and to evaluate the hypothesis that these compounds may stimulate the release of NO in cerebral circulation. We predicted that intra-arterial infusions of Lys1-AngIV, Nle1-AngIV and Norleucinal would increase CBF without influencing systemic blood pressure, and that an NO synthase inhibitor, Nw-nitro-l-arginine methyl ester (l-NAME), would block these AngIV- and AngIV analog-induced responses in the cerebral microvasculature.

Section snippets

Animals and maintenance

Female Sprague–Dawley rats (Taconic Farms, Germantown, NY, derived), weighing 250–350 g, were bred and housed in group cages in an American Association for Accreditation of Laboratory Animal Care-approved vivarium under a 12:12 h light/dark cycle initiated at 07:00 h at 22±1°C with free access to Purina laboratory chow and water.

Surgery and instrumentation

Each animal utilized in experiments 1 and 2 was initially pretreated with an intramuscular injection of diazepam (2.5 mg/kg, Parke Davis, St. Louis, MO) 10 min prior to

Experiment 1: AngIV analog-induced pressor and CBF effects

The maximum changes in systemic blood pressure during the infusion of AngIV and AngIV analogs in experiment 1 are listed for groups 1–5 in Table 2. The groups used to test for the effects of AngIV, and AngIV analogs, on systemic blood pressure and CBF did not differ regarding baseline blood pressure (overall mean±S.E.M.=110.0±1.3 mmHg; F=1.12, df 4/35, P>0.10). The maximum change in MAP during the pretreatment and treatment period was also shown to have no groups effect (F=1.17, df 5/36, P

Discussion

The recent discovery of an AT4 receptor subtype that binds AngIV has generated several investigations concerning its roles within the brain-renin angiotensin system. Initial studies revealed that this AT4 receptor is localized in species ranging from arthropods to mammals, and in a wide range of tissue beds including heart, lung, brain, bladder, spleen, thymus, adrenals, kidney, gut, spinal cord, pituitary and vascular endothelial and smooth muscle cells 23, 24, 33, 34. It appears that the AT4

Acknowledgements

We wish to extend our thanks to Bryan Slinker for statistical consultation. This investigation was supported by funds provided by Washington State University, Hedral Therapeutics, and The Laing Endowment for research on Alzheimer's Disease.

References (46)

  • KL Hall et al.

    Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells

    Regul Pept

    (1995)
  • LT Krebs et al.

    Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist

    Regul Pept

    (1996)
  • EA Kramár et al.

    Angiotensin II- and IV-induced changes in cerebral blood flow: roles of AT1, AT2, and AT4 receptor subtypes

    Regul Pept

    (1997)
  • MF Sardinia et al.

    AT4 receptor binding characteristics: d-amino acid- and glycine-substituted peptides

    Peptides

    (1993)
  • MF Sardinia et al.

    AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues

    Peptides

    (1994)
  • I Møeller et al.

    Localization of angiotensin IV binding sites to motor and sensory neurons in the sheep spinal cord and hindbrain

    Brain Res

    (1995)
  • J.W. Wright et al.

    Important roles for angiotensin III and IV in the brain renin-angiotensin system

    Brain Res Rev

    (1997)
  • JW Wright et al.

    Angiotensin II(3-8) [Ang IV] hippocampal binding: potential role in the facilitation of memory

    Brain Res Bull

    (1993)
  • JW Wright et al.

    Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats

    Brain Res

    (1996)
  • I Møeller et al.

    Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurones

    Brain Res

    (1996)
  • Q. Yang et al.

    The AT4 receptor agonist [Nle1]-angiotensinIV reduces mechanically induced immediate-early glial expression in isolated rabbit heart

    Regul Pept

    (1997)
  • J.K.M. Coleman et al.

    Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats

    Peptides

    (1998)
  • JL Cummings et al.

    Amnesia with hippocampal lesions after cardiopulmonary arrest

    Neurology

    (1984)
  • Cited by (54)

    • Molecular basis of the therapeutic properties of hemorphins

      2020, Pharmacological Research
      Citation Excerpt :

      Reports have shown an increased cerebral microcirculation when AngIV was administered in the carotid artery of anesthetized rats [120]. This effect was attributed to the stimulation of endothelial production of nitric oxide by AngIV [121]. To achieve the same results, intracerebroventricular injections of both LVV-hemorphin-7 and AngIV were given to anesthetized rats, but surprisingly, both failed to alter hippocampal blood flow in vivo compared to control animals in the plus maze or control chamber [115].

    • Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease

      2020, Neurobiology of Disease
      Citation Excerpt :

      AngIV reestablished dilatory function and NO bioavailability in brain vessels, which was associated with normalized endothelial TRPV4 channel function involving intermediate and small conductance Ca2+ sensitive K+ channels (Zhang et al., 2013b), and m5 muscarinic ACh receptor-induced NO release (Elhusseiny and Hamel, 2000). These benefits agree with the positive effects of AngIV on endothelial function and NO production in systemic or brain vessels (Kramar et al., 1998; Vinh et al., 2008). AngIV's ability to activate eNOS through post-transcriptional modulation, facilitate NO synthesis and release from endothelial cells, and stimulate cGMP accumulation, provides mechanisms through which endothelial function may be rescued (Kramar et al., 1998; Royea et al., 2017; Vinh et al., 2008).

    • The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

      2015, Progress in Neurobiology
      Citation Excerpt :

      Treatment with HGF was also found to increase the number of arteries in the neocortex some 50 days following the onset of ischemia. In sum, these results suggest a role for the HGF/c-Met receptor system in cerebroprotection and are consistent with the notion that AngIV increases blood flow by a NO-dependent mechanism (Kramár et al., 1998). As previously mentioned Faure et al. (2006) have reported that increasing doses of AngIV via the internal carotid artery significantly decreased mortality and cerebral infarct size in rats 24 h following embolic stroke due to the intracarotid injection of calibrated microspheres.

    • Brain renin-angiotensin-A new look at an old system

      2011, Progress in Neurobiology
      Citation Excerpt :

      Both AP-A and AP-N have been localized to the plasma membrane of pericytes suggesting that AngIV is found in the extracellular space surrounding microvessels in the brain (Healy and Wilk, 1993; Kunz et al., 1994). In support of this notion exogenous administration of Ang IV has been shown to increase cerebral microcirculation (Kramár et al., 1997, 1998; Naveri et al., 1994). Lanckmans et al. (2007a,b) measured AngIV in the striatum using microdialysis coupled with a sensitive liquid chromatography mass spectrometry system.

    • Activation of the Renin-Angiotensin System in Heart Failure

      2010, Heart Failure: A Companion to Braunwald's Heart Disease Expert Consult
    View all citing articles on Scopus
    View full text